Results of 2022 Annual General Meeting
10/06/2022 11:21
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220610:nRSJ4909Oa&default-theme=true
RNS Number : 4909O Ergomed plc 10 June 2022
PRESS RELEASE
Results of 2022 Annual General Meeting
Guildford, 10 June 2022: Ergomed plc (AIM: ERGO) ("Ergomed" or the "Company"),
a company focused on providing specialised services to the pharmaceutical
industry, announces the results of voting on the resolutions put to
shareholders at its Annual General Meeting ("AGM") held earlier today. All
Resolutions were duly passed.
Details of the voting by way of a poll at the AGM in respect of each
resolution are shown in the table below:
Resolution number Resolution Votes for Votes against Abstentions
1 Accounts 40,070,518 0 1,492,956
2 Reappoint auditor 41,493,555 69,125 794
3 Reappoint John Dawson 41,454,634 107,895 945
4 Reappoint Mark Enyedy 34,200,041 7,362,488 945
5 Reappoint Michael Spiteri 32,439,508 9,123,278 688
6 Allot securities 39,399,013 2,163,803 658
7 Pre-emption rights 39,808,724 1,754,493 257
8 Pre-emption rights 39,699,675 1,863,542 257
9 Amendment to Articles of Association 41,563,066 0 408
The full text of all resolutions can be found in the Notice of Annual General
Meeting on the Company's website www.ergomedplc.com
Ergomed's Board engage with the Company's shareholders and other stakeholders
to understand their views. Whilst all resolutions were passed, shareholders
representing over 20% of votes cast voted against Resolution 5 and the Board
will re-engage with them to better understand their position.
ENDS
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 402 975
Dr Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets & Strategy)
Numis
Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP
Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher Golden
Consilium Strategic
Communications
Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal
ergomed@consilium-comms.com
Angela Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing services business includes an
industry-leading suite of specialist pharmacovigilance (PV) solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
clinical research and trial management services under the Ergomed brand (CRO)
and mission-critical regulatory compliance and consulting services under the
ADAMAS brand. For further information, visit: http://ergomedplc.com
(http://ergomedplc.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END RAGEAEKEFFPAEFA